Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 54
- Registration Number
- NCT01995058
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 509
- Registration Number
- NCT01995513
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇧🇪Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 158
- Registration Number
- NCT01972217
- Locations
- 🇬🇧
Research Site, Westcliff-on-Sea, United Kingdom
Abiraterone Acetate for Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01961843
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1173
- Registration Number
- NCT01957436
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Vall d'Hebron University Hospital, Barcelona, Spain
🇪🇸ICO Girona - Hospital Josep Trueta, Girona, Spain
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1311
- Registration Number
- NCT01949337
- Locations
- 🇺🇸
Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT01946165
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Duke University
- Target Recruit Count
- 100
- Registration Number
- NCT01940276
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Birmingham VA Medical Center, Birmingham, Alabama, United States
🇺🇸Tulane Cancer Center, New Orleans, Louisiana, United States
Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT01913015
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Participants
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01873001
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.